EUVIMEDEUVIMED entdecken
Crossref

Personalized Prediction of Uterine Fibroid Shrinkage During GnRH Antagonist Treatment via Pretreatment T2 ‐Weighted MRI Signal Intensity

Shigenobu Motoshima iD, Hiroyuki Nomiyama, Kenyu Hashimoto iD, Hideyuki Miyahara iD, Kenta Murotani iD, Kosuke Kawakami iD, Hiroki Ishibashi iD, Naofumi Okura, Toshiyuki Yoshizato iD

Journal of Obstetrics and Gynaecology Research · 2026

DOI: 10.1111/jog.70530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Shigenobu Motoshima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, NHO Kokura Medical Center, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Leiomyoma, Gonadotropin-Releasing Hormone, Magnetic Resonance Imaging, Uterine Neoplasms. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To develop and internally validate a pretreatment quantitative magnetic resonance imaging‐based predictive model for uterine fibroid volume reduction following gonadotropin‐releasing hormone antagonist therapy.

Methods

In this single‐center retrospective study, 106 women with uterine fibroids treated with relugolix underwent pre‐ and intratreatment magnetic resonance imaging. The dominant fibroid was assessed for T2‐weighted imaging fibroid‐to‐iliopsoas signal intensity ratio, apparent diffusion coefficient, flow voids, and fibroid location. The primary outcome was a ≥ 30% reduction in dominant fibroid volume between pre and intratreatment magnetic resonance imaging. Eight baseline variables were entered into a Least Absolute Shrinkage and Selection Operator‐penalized logistic regression model with bootstrap internal validation.

Results

Sixty patients (56.6%) achieved a ≥ 30% volume reduction. In the univariate analyses, a higher T2‐weighted imaging signal intensity ratio and location were significantly associated with response. A purely data‐driven Least Absolute Shrinkage and Selection Operator model retained two predictors: dichotomized T2‐weighted imaging signal intensity ratio and location. A T2‐weighted imaging ratio ≥ 2.0 was the strongest positive predictor, whereas subserosal and cervical locations showed negative associations and submucosal location showed a slight positive association relative to intramural fibroids. The model showed moderate discrimination (apparent area under the receiver operating characteristic curve, 0.746; optimism‐corrected area, 0.671) with acceptable calibration.

Conclusions

Quantitative pretreatment T2‐weighted imaging (ratio ≥ 2.0) is strongly associated with fibroid volume reduction under gonadotropin‐releasing hormone antagonist therapy. An internally validated Least Absolute Shrinkage and Selection Operator‐based model incorporating T2‐weighted imaging signal intensity and location may aid individualized treatment selection and preoperative planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeiomyomaGonadotropin-Releasing HormoneMagnetic Resonance ImagingUterine NeoplasmsHormone AntagonistsHumansFemaleRetrospective StudiesAdultMiddle Aged

Stichwörter der Autor:innen

magnetic resonance imagingprecision medicinepreoperative planningrelugolixuterine fibroids

Substanzen

Gonadotropin-Releasing HormoneLHRH, Ala(6)-Gly(10)-ethylamide-Hormone Antagonists

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, NHO Kokura Medical Center, Kitakyushu, Japan.
  • Department of Radiology, NHO Kokura Medical Center, Kitakyushu, Japan.
  • Department of Clinical Investigation, Kumamoto University Hospital, Kumamoto, Japan.
  • Biostatistics Center, Kurume University, Kurume, Japan.
  • School of Medical Technology, Kurume University, Kurume, Japan.
  • Tobata Kyoritsu Hospital, Kitakyushu, Japan.

ORCID-Profile: Shigenobu Motoshima, Kenyu Hashimoto, Hideyuki Miyahara, Kenta Murotani, Kosuke Kawakami, Hiroki Ishibashi, Toshiyuki Yoshizato

Zitieren

APA

Motoshima, S., Nomiyama, H., Hashimoto, K., Miyahara, H., Murotani, K., Kawakami, K., Ishibashi, H., Okura, N., & Yoshizato, T. (2026). Personalized Prediction of Uterine Fibroid Shrinkage During GnRH Antagonist Treatment via Pretreatment T2 ‐Weighted MRI Signal Intensity. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70530

Vancouver

Motoshima S, Nomiyama H, Hashimoto K, Miyahara H, Murotani K, Kawakami K, et al. Personalized Prediction of Uterine Fibroid Shrinkage During GnRH Antagonist Treatment via Pretreatment T2 ‐Weighted MRI Signal Intensity. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70530

BibTeX
@article{Motoshima2026,
  author = {Motoshima, Shigenobu and Nomiyama, Hiroyuki and Hashimoto, Kenyu and Miyahara, Hideyuki and Murotani, Kenta and Kawakami, Kosuke and Ishibashi, Hiroki and Okura, Naofumi and Yoshizato, Toshiyuki},
  title = {Personalized Prediction of Uterine Fibroid Shrinkage During GnRH Antagonist Treatment via Pretreatment T2 ‐Weighted MRI Signal Intensity},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  doi = {10.1111/jog.70530}
}
Kostenlos starten →